Selective inhibition of IL-2 gene expression by IL-2 antisense oligonucleotides blocks heart allograft rejection.
OBJECTIVE
We tested the effects of selective inhibition of interleukin (IL)-2 gene expression by IL-2 antisense oligonucleotide (oligo) with phosphorothioate (PS)/phosphodiester (PD)/2'-methoxyethyl (ME) modifications (17359) on T-cell function and the survival of heart allografts in mice.


METHODS
The PS- (17328) or PS/PD/ME- (17359) IL-2 oligo was electroporated to mouse T cell lymphoma cells (TIB 155) stimulated with concanavalin A (Con A). Expression of IL-2 was analyzed by an ELISA spot assay and a reverse transcript polymerase chain reaction method. C3H (H-2k) mice transplanted with BALB/c (H-2d) heart grafts were treated i.v. with a 7-day osmotic pump with 20 mg/kg 17359 alone or in combination with sirolimus (SRL).


RESULTS
In comparison with untreated controls, 500 to 2000 nM 17328 inhibited IL-2 protein production by 21.8% to 47.2%, whereas 500 to 2000 nM 17359 did so by 35.5% to 83.5% (both P<0.001). In vivo, 20 mg/kg 17359 prolonged survivals to a mean survival time (MST) of 18.3+/-2.6 days (P<0.001) in comparison with only 8.2+/-0.8 days in untreated controls. Although 0.2 mg/kg SRL alone produced a MST of 18.8+/-6.0 days (P<0.01), addition of 20 mg/kg 17539 synergistically extended survivals to 54.3+/-12.1 days (P<0.001). As expected, IL-2 mRNA, but not IL-7, IL-9, or IL-15 mRNA, was reduced in allografts from recipients treated with 17359 compared with untreated controls. Lymph node cells from the same recipients displayed reduction in proliferative response to donor alloantigen and in generation of alloantigen-specific cytotoxic T cells.


CONCLUSIONS
Selective inhibition of IL-2 mRNA in vivo inhibits T-cell function and extends allograft survival.
Qu
X
X
Division of Immunology and Organ Transplantation, Department of Surgery, The University of Texas Medical School-Houston, 6431 Fannin, Suite 6.240, Houston, TX 77030, USA.
Kirken
R A
RA
Tian
L
L
Wang
M
M
Bennett
C F
CF
Stepkowski
S M
SM
D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D015870:Gene Expression / Q000187:drug effects; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D016027:Heart Transplantation / Q000009:adverse effects / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D020319:Oligodeoxyribonucleotides, Antisense / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D020123:Sirolimus / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D020319:Oligodeoxyribonucleotides, Antisense; D020123:Sirolimus